Peapod Lane Capital LLC Purchases Shares of 553,816 Climb Bio, Inc. (NASDAQ:CLYM)

Peapod Lane Capital LLC purchased a new stake in shares of Climb Bio, Inc. (NASDAQ:CLYM - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 553,816 shares of the company's stock, valued at approximately $676,000. Peapod Lane Capital LLC owned approximately 0.82% of Climb Bio at the end of the most recent reporting period.

Separately, Bank of New York Mellon Corp purchased a new position in shares of Climb Bio in the first quarter worth $79,000. Institutional investors and hedge funds own 69.76% of the company's stock.

Wall Street Analysts Forecast Growth

CLYM has been the topic of several research analyst reports. BTIG Research initiated coverage on shares of Climb Bio in a report on Thursday, May 22nd. They issued a "buy" rating on the stock. Oppenheimer initiated coverage on shares of Climb Bio in a report on Friday, June 6th. They issued an "outperform" rating and a $10.00 target price on the stock.

Climb Bio Price Performance

Shares of CLYM stock remained flat at $1.35 during mid-day trading on Thursday. 137,351 shares of the stock traded hands, compared to its average volume of 294,059. Climb Bio, Inc. has a 1 year low of $1.05 and a 1 year high of $9.21. The company has a 50-day simple moving average of $1.25 and a 200 day simple moving average of $1.45. The stock has a market capitalization of $91.23 million, a P/E ratio of -0.57 and a beta of -0.13.

Climb Bio (NASDAQ:CLYM - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.16). As a group, equities analysts expect that Climb Bio, Inc. will post -1.57 earnings per share for the current year.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.